Yes, Neffy Treats Anaphylaxis
Neffy (epinephrine nasal spray) is FDA-approved for emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing at least 30 kg (66 lbs). It delivers 2 mg epinephrine intranasally to rapidly reverse symptoms like airway swelling, low blood pressure, and hives caused by severe allergic reactions to foods, insect stings, or medications.[1]
How Neffy Works for Anaphylaxis
Neffy uses a single-use nasal spray that propels epinephrine into the nasal cavity, where it absorbs quickly into the bloodstream—reaching peak levels in about 20-30 minutes, similar to IM injections like EpiPen. It's needle-free, making it easier for bystanders or patients to administer during an emergency.[1][2]
Who Can Use Neffy and When
Approved for patients 30 kg and up; a separate 1 mg version exists for children 15-30 kg. Use at the first sign of anaphylaxis, such as difficulty breathing or throat tightness. Always call 911 after use, as a second dose may be needed after 5 minutes.[1]
Neffy vs. EpiPen: Key Differences
| Feature | Neffy | EpiPen |
|---------|--------|--------|
| Delivery | Nasal spray (2 mg dose) | IM injection (0.3 mg auto-injector) |
| Storage | Room temperature, no shaking | Avoid extreme temps, shake if needed |
| Cost (list price) | ~$725 for 2-pack | ~$700 for 2-pack |
| Availability | Prescription, launched 2024 | Prescription, long-established |
Neffy avoids needles, reducing hesitation in emergencies, but nasal congestion from anaphylaxis may slightly slow absorption compared to injections.[2][3]
Common Side Effects and Risks
Patients report nasal discomfort, runny nose, or headache. Rare risks include irregular heartbeat or high blood pressure, especially if overused. Not for mild allergies—reserved for life-threatening anaphylaxis.[1]
Availability, Pricing, and Insurance
Available by prescription since August 2024 from ARS Pharmaceuticals. List price matches EpiPen at $724.80 for a two-dose carton, but copays as low as $25 with savings cards. Medicare Part D covers it.[3]
Patent Status and Biosimilars
Neffy has U.S. patents through 2041 (e.g., US 11,246,536 for nasal formulation). No generics yet; exclusivity until at least 2029.[4]
[1]: FDA Approval Letter for NEFFY (ARS Pharmaceuticals, Aug 9, 2024). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216232Orig1s000Approv.pdf
[2]: NEFFY Prescribing Information. https://neffy.com/wp-content/uploads/2024/08/NEFFY-PI-08.2024.pdf
[3]: ARS Pharmaceuticals Press Release (Aug 9, 2024). https://ir.arspharma.com/news-releases/news-release-details/ars-pharmaceuticals-receives-fda-approval-neffy-epinephrine-nasal
[4]: DrugPatentWatch.com (Neffy patents). https://www.drugpatentwatch.com/p/tradename/NEFFY